Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC).The analyst commented, "One concern we have ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE